- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00954876
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
October 18, 2022 updated by: Translational Genomics Research Institute
Phase II, Multi-Center, Open-Label, Prospective Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type KRAS Colorectal Cancer Who Are Considered Nonoptimal Candidates or Are Intolerant to a First-Line Oxaliplatin/Irinotecan Regimen
The combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with KRAS wild type colorectal cancer.
Patients who are not able or willing to take Oxaliplatin/Irinotecan combination therapy are eligible for this study.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Spokane, Washington, United States, 99218
- Evergreen Hematology & Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Metastatic colorectal cancer
- Tumor classified WT KRAS
- At least 18 yrs of age
- ECOG PS 0,1 or 2
- Evidence of adequate organ function
- Measurable disease per RECIST criteria
Have at least two of the following criteria:
- Age > 65 years
- ECOG PS 1 or 2
- Serum Albumin < or equal to 3.5g/dL
- Prior RT to abdomen or pelvis
- Stopped first-line combination systemic chemotherapy < 6 weeks duration
Exclusion Criteria
- Tumors classified as KRAS mutation
- Prior therapy with cetuximab, panitumumab or other agent that targets EGFR
- Prior exposure to any biologic
- Known sensitivity to cetuximab or 5-FU (or marked intolerance to 5-FU)
- Known DPD deficiency
- Uncontrolled angina or a myocardial infarction within the previous 12 months
- Concurrent severe uncontrolled medical illness
- Known uncontrolled CNS metastases
- Bowel disease associated with chronic diarrhea
- Major surgery within 28 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the response rate in patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab
Time Frame: 18 months
|
18 months
|
To assess the overall survival rate among patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab
Time Frame: 18 months
|
18 months
|
To characterize the toxic effects and AEs of the combination regimen of capecitabine and cetuximab in this patient population
Time Frame: every three months
|
every three months
|
To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.
Time Frame: 1 year after study closure
|
1 year after study closure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ramesh Ramanathan, M.D., Translational Genomics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (ACTUAL)
January 1, 2010
Study Completion (ACTUAL)
January 1, 2010
Study Registration Dates
First Submitted
July 17, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (ESTIMATE)
August 7, 2009
Study Record Updates
Last Update Posted (ACTUAL)
October 20, 2022
Last Update Submitted That Met QC Criteria
October 18, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Capecitabine
- Cetuximab
Other Study ID Numbers
- MED-P02-07003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on capecitabine and cetuximab
-
King Faisal Specialist Hospital & Research CenterCompletedColon Rectal Cancer Duke Stage StagevalSaudi Arabia
-
Sun Yat-sen UniversityActive, not recruiting
-
University of Medicine and Dentistry of New JerseyBristol-Myers Squibb; Rutgers Cancer Institute of New JerseyTerminatedColorectal CancerUnited States
-
Institute of Oncology LjubljanaUnknown
-
Swiss Group for Clinical Cancer ResearchCompleted
-
National University Hospital, SingaporeUnknown
-
Peking UniversityMerck Sharp & Dohme LLCCompleted
-
Abramson Cancer Center of the University of PennsylvaniaBristol-Myers Squibb; Roche Pharma AGTerminated
-
Huazhong University of Science and TechnologyThe First Affiliated Hospital of Nanchang University; Henan Cancer Hospital; Hunan...Unknown
-
Wales Cancer Trials UnitCancer Research UKUnknownEsophageal CancerUnited Kingdom